Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUTIA: Intra-arterial 177Lu-dotatate for NET Liver Metastases
NCT03590119Phase 3Completed
- Start
- Aug 2018
- Primary completion
- Sep 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in Neuroendocrine Neoplasm (NEN). Started Aug 2018; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03590119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03590119.